SELAS PHARMACIE DU CARREFOUR SAINT DENIS : revenue, balance sheet and financial ratios

SELAS PHARMACIE DU CARREFOUR SAINT DENIS is a French company founded 16 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SAINT-DENIS (93200), this company of category PME shows in 2020 a revenue of 2.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELAS PHARMACIE DU CARREFOUR SAINT DENIS (SIREN 520764986)
Indicator 2024 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C 2 301 036 € 2 671 471 € 2 795 513 € 2 717 768 € 2 957 125 €
Net income 55 845 € -33 216 € 120 434 € 79 293 € 205 261 € 167 817 € 197 117 € 259 368 €
EBITDA N/C N/C N/C 125 651 € 303 510 € 255 377 € 317 113 € 423 730 €
Net margin N/C N/C N/C 3.4% 7.7% 6.0% 7.3% 8.8%

Revenue and income statement

In 2024, SELAS PHARMACIE DU CARREFOUR SAINT DENIS generates positive net income of 56 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 259 k€ -> 56 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

55 845 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 123%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 35%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

123.481%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

34.582%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

90.6%

Solvency indicators evolution
SELAS PHARMACIE DU CARREFOUR SAINT DENIS

Sector positioning

Debt ratio
123.48 2024
2021
2022
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average +23 pts over 3 years

In 2024, the debt ratio of SELAS PHARMACIE DU CARREF... (123.48) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
34.58% 2024
2021
2022
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average -29 pts over 3 years

In 2024, the financial autonomy of SELAS PHARMACIE DU CARREF... (34.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 182.91. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

182.912

Liquidity indicators evolution
SELAS PHARMACIE DU CARREFOUR SAINT DENIS

Sector positioning

Liquidity ratio
182.91 2024
2021
2022
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Good -25 pts over 3 years

In 2024, the liquidity ratio of SELAS PHARMACIE DU CARREF... (182.91) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELAS PHARMACIE DU CARREFOUR SAINT DENIS

Positioning of SELAS PHARMACIE DU CARREFOUR SAINT DENIS in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELAS PHARMACIE DU CARREFOUR SAINT DENIS is estimated at 779 637 € (range 542 927€ - 1 166 382€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
542k€ 779k€ 1166k€
779 637 € Range: 542 927€ - 1 166 382€
NAF 5 année 2024

Valuation method used

Net Income Multiple
55 845 € × 14.0x = 779 637 €
Range: 542 927€ - 1 166 382€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELAS PHARMACIE DU CARREFOUR SAINT DENIS with other companies in the same sector:

Frequently asked questions about SELAS PHARMACIE DU CARREFOUR SAINT DENIS

What is the revenue of SELAS PHARMACIE DU CARREFOUR SAINT DENIS ?

The revenue of SELAS PHARMACIE DU CARREFOUR SAINT DENIS in 2020 is 2.3 M€.

Is SELAS PHARMACIE DU CARREFOUR SAINT DENIS profitable?

Yes, SELAS PHARMACIE DU CARREFOUR SAINT DENIS generated a net profit of 56 k€ in 2024.

Where is the headquarters of SELAS PHARMACIE DU CARREFOUR SAINT DENIS ?

The headquarters of SELAS PHARMACIE DU CARREFOUR SAINT DENIS is located in SAINT-DENIS (93200), in the department Seine-Saint-Denis.

Where to find the tax return of SELAS PHARMACIE DU CARREFOUR SAINT DENIS ?

The tax return of SELAS PHARMACIE DU CARREFOUR SAINT DENIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELAS PHARMACIE DU CARREFOUR SAINT DENIS operate?

SELAS PHARMACIE DU CARREFOUR SAINT DENIS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.